STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD®
) Device, in Healthy Adult Subjects
2019 ◽
Vol 59
(3)
◽
pp. 394-409
◽